肾癌生物治疗的研究进展  

Advance in biotherapy for renal cell carcinoma

作　　者：李科[1] 苏泽轩[1] 李君武[2] 

机构地区：[1]暨南大学附属第一医院,广东广州510630 [2]暨南大学医学院,广东广州510632

出　　处：《中国医学工程》2008年第4期279-282,共4页China Medical Engineering

摘　　要：肾细胞癌是泌尿系统肿瘤中常见的恶性肿瘤,近几年发病率呈增长的趋势。由于该肿瘤对放、化疗及内分泌治疗效果均不理想,目前仍然以传统手术治疗为主。伴随分子生物学、免疫学、基因工程技术的迅速发展,肾细胞癌也以其特殊的生物学特性使其在细胞因子类药物治疗、肾癌疫苗治疗以及分子靶向治疗等生物免疫治疗方面显示出良好的应用前景。Renal cell carcinoma (RCC) is one of the most frequent urologic malignancies and its incidence is in-creasing in these years. Because conventional radiotherapy,chemotherapy and endocrine therapy are ineffective for the majority of RCC,surgical therapy is still the main treatment at present. Along with the development of molecular biology,immunology and gene engineering,immunotherapeutic treatments for RCC,including gene,dendritic cell,vaccine represent a bright prospect. This paper overviews the advancement in biotherapy of renal cell carcinoma in recent years.

关 键 词：肾肿瘤 生物治疗 

分 类 号：R737.11[医药卫生—肿瘤]